New hope for japanese AML patients: experimental drug ziftomenib enters trial
NCT ID NCT07623616
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ziftomenib in 6 Japanese adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drug is taken as a pill once daily. The goal is to see if it can help control the disease and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ziftomenib
What this could lead to
If successful, this could point toward a new treatment option for Japanese patients with a specific type of AML that has come back or not responded to other therapies.
What could go wrong
This is a very small, early-phase study with only 6 participants, so results may not apply broadly. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chiba Aoba Municipal Hospital
RECRUITINGChiba, Japan
-
Dokkyo Medical University Hospital
RECRUITINGTochigi, Japan
-
Gifu Municipal Hospital
RECRUITINGGifu, Japan
-
Hyogo Medical University Hospital
NOT_YET_RECRUITINGHyōgo, Japan
-
Imamura General Hospital
RECRUITINGKagoshima, Japan
-
Jichi Medical University Hospital
RECRUITINGTochigi, Japan
-
Jichi Medical University Saitama Medical Center
NOT_YET_RECRUITINGSaitama, Japan
-
Kanagawa Cancer Center
RECRUITINGKanagawa, Japan
-
Kansai Medical University Hospital
RECRUITINGOsaka, Japan
-
Keio University Hospital
NOT_YET_RECRUITINGTokyo, Japan
-
Kurashiki Central Hospital
RECRUITINGOkayama, Japan
-
Kyoto University Hospital
NOT_YET_RECRUITINGKyoto, Japan
-
Matsumoto National Hospital
RECRUITINGNagano, Japan
-
Mito Medical Center
RECRUITINGIbaraki, Japan
-
Nagasaki University Hospital
RECRUITINGNagasaki, Japan
-
Nippon Medical School Hospital
NOT_YET_RECRUITINGTokyo, Japan
-
Okayama University Hospital
RECRUITINGOkayama, Japan
-
Osaka Metropolitan University Hospital
RECRUITINGOsaka, Japan
-
Tohoku University Hospital
RECRUITINGMiyagi, Japan
-
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
RECRUITINGTokyo, Japan